Advanced generation anti-prostate specific membrane antigen designer T cells for prostate cancer immunotherapy (Q39068511)

8 September 2017

title

Advanced generation anti-prostate specific membrane antigen designer T cells for prostate cancer immunotherapy (English)

1 reference

8 September 2017

1 reference

1 reference

Qiangzhong Ma

1 reference

8 September 2017

Erica M Gomes

series ordinal

1 reference

8 September 2017

Agnes Shuk-Yee Lo

series ordinal

1 reference

8 September 2017

Richard P Junghans

series ordinal

1 reference

8 September 2017

publication date

1 February 2014

1 reference

8 September 2017

1 reference

8 September 2017

1 reference

8 September 2017

1 reference

8 September 2017

page(s)

286-296

1 reference

Anti-prostate specific membrane antigen designer T cells for prostate cancer therapy

8 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22749

Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22749

Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ /CD28 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22749

Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22749

Treating cancer with genetically engineered T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22749

CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22749

CD28/B7 costimulation: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22749

Redirecting mouse CTL against colon carcinoma: superior signaling efficacy of single-chain variable domain chimeras containing TCR-zeta vs Fc epsilon RI-gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22749

Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chain

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22749

Second-generation anti-carcinoembryonic antigen designer T cells resist activation-induced cell death, proliferate on tumor contact, secrete cytokines, and exhibit superior antitumor activity in vivo: a preclinical evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22749

Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell-mediated tumor eradication

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22749

Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22749

Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22749

Memory T cells originate from adoptively transferred effectors and reconstituting host cells after sequential lymphodepletion and adoptive immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22749

Host lymphodepletion augments T cell adoptive immunotherapy through enhanced intratumoral proliferation of effector cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22749

A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22749

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22749

Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22749

CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22749

Rejection of Syngeneic Colon Carcinoma by CTLs Expressing Single-Chain Antibody Receptors Codelivering CD28 Costimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22749

21 January 2018

Identifiers

DOI

10.1002/PROS.22749

1 reference

8 September 2017

1 reference